What Changed
Price Move History
- Daily moves over 5%
- 34 252 sessions, November 4, 2025 to November 4, 2026
- Largest daily move
- -38.1% close of October 30, 2026
- 1-year change
- -57.4% closing prices, November 4, 2025 to November 4, 2026
- 1-month change
- -17.4% closing prices, October 2, 2026 to November 4, 2026
Company Description
Alphatec Holdings, Inc. (Nasdaq: ATEC) is a medical device company focused on the surgical treatment of spinal disorders. According to the company, ATEC is dedicated to revolutionizing the approach to spine surgery through clinical distinction, with a spine-only focus and a vision "to be the Standard Bearer in Spine." Through its wholly owned subsidiaries Alphatec Spine, Inc., EOS imaging S.A.S., and SafeOp Surgical, Inc., the company develops and commercializes technologies intended to make spine surgery more informed, reproducible, and outcome-driven.
Alphatec is described as a spine-focused provider of solutions that support procedures addressing complex pathologies of the thoracolumbar spine and other spinal conditions associated with disease, degeneration, deformity, trauma, tumor, infection, and related indications. Earlier descriptions also note that the company designs, develops, and advances products for the surgical treatment of spinal disorders, including approaches such as Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion.
Spine-focused procedural ecosystems
ATEC emphasizes a procedural, ecosystem-based approach to spine surgery. Management frequently refers to an "end-to-end procedural ecosystem" and "procedural spine solutions" that integrate data, informatics, imaging, navigation, and instrumentation. The company highlights that its solutions are architected to drive clinical distinction and more predictable surgical outcomes, with particular attention to complex spine surgeries.
A core element of this strategy is the Organic Innovation Machine™, which the company describes as its engine for developing new approaches that integrate seamlessly with its expanding informatics platforms. These platforms are referenced as InformatiX™ and AlphaInformatiX in company communications and are intended to better inform surgery and more safely and reproducibly achieve the goals of spine surgery.
Key platforms, technologies, and subsidiaries
Alphatec operates through several specialized subsidiaries and technology platforms:
- Alphatec Spine, Inc. – The primary spine business, focused on procedural spine solutions and surgical technologies.
- EOS imaging S.A.S. – Referenced as contributing EOS revenue and associated with EOS Insight®, which the company notes is seeing increased adoption. EOS-related offerings are integrated into ATEC’s spine ecosystem and reported as a distinct revenue component.
- SafeOp Surgical, Inc. – Associated with the SafeOp™ Neural InformatiX™ System, which is described as delivering objective and actionable information through neurophysiologic monitoring capabilities such as motor evoked potentials (MEPs), surgeon-directed Delta™ tEMG for lumbar plexus localization, and real-time femoral nerve health monitoring with automated SSEPs.
ATEC also highlights proprietary approaches and systems within its procedural portfolio. For example, its Prone TransPsoas (PTP™) and Lateral TransPsoas (LTP™) approaches are cited as key drivers of surgical revenue growth and surgeon adoption. The company describes PTP as part of a fully integrated offering that includes positioning, access, implants, and neuro-monitoring.
PTP™ Corpectomy and complex spine solutions
Alphatec has announced the commercial launch of its PTP™ Corpectomy system, which it characterizes as the next evolution of lateral approach surgery. This system extends the PTP approach to deformity and corpectomy procedures for complex thoracolumbar pathologies, including cases involving tumor, trauma, infection, and deformity.
The PTP Corpectomy solution, as described by the company, includes:
- Sigma™ LIF Corpectomy Access System – Designed to optimize lateral corpectomy exposure of the thoracolumbar spine, with retractor versatility and customizable exposure in prone (PTP) and lateral decubitus (LTP™) positions.
- Ascend™ NanoTec™ Vertebral Body Replacement (VBR) System – An expandable, anatomy-driven vertebral body replacement system with NanoTec surface treatment technology intended to enhance bone growth in complex spinal reconstruction.
- SafeOp™ Neural InformatiX™ System – Providing intraoperative neurophysiologic information to support safer lateral corpectomy and other spine procedures.
These systems are presented as working together within ATEC’s integrated PTP offering, with the goal of improving access, minimizing risk, and supporting better patient outcomes in complex spine surgeries.
Biologics and regenerative medicine partnership
Alphatec has entered into a definitive strategic partnership with Theradaptive, Inc., a clinical-stage regenerative medicine company. Under this agreement, ATEC gains exclusive U.S. commercial rights to market and distribute OsteoAdapt®, an osteoinductive bone graft for spinal fusion that is built on Theradaptive’s proprietary AMP2™ protein technology. The companies describe OsteoAdapt as being evaluated in clinical trials in spine and dental applications and subject to FDA PMA approval, with three FDA Breakthrough Device Designations.
ATEC characterizes this partnership as an important milestone in the evolution of its procedural ecosystem, adding a biologic solution intended to enhance fusion outcomes. Company communications describe OsteoAdapt as a next-generation rhBMP-2 solution designed to deliver potent bone formation with greater precision at the fusion site, enabling lower doses, simpler handling, and an improved safety profile versus legacy biologics, and to address market concentration in the rhBMP-2 segment.
Revenue mix and growth drivers (structural, not numeric)
While specific financial figures change over time, ATEC’s public disclosures provide insight into how its business is structured. The company reports revenue in at least two primary categories: surgical revenue and EOS revenue. Surgical revenue is associated with spine procedures and related technologies, while EOS revenue is tied to EOS imaging-related offerings.
Management commentary emphasizes several recurring growth drivers:
- Surgical volume growth and average revenue per procedure, reflecting adoption of ATEC’s procedural solutions.
- New surgeon adoption and growth in net new surgeon users, cited as key leading indicators of future growth.
- Expansion of procedural ecosystems such as PTP and LTP, and increased adoption of EOS Insight®.
- Integration of biologics like OsteoAdapt into the company’s procedural offerings.
The company also regularly discusses non-GAAP measures such as adjusted EBITDA, non-GAAP gross margin, and free cash flow, which it presents as tools for evaluating core operating performance and capital efficiency.
Capital markets presence and communications
Alphatec’s common stock trades on the Nasdaq exchange under the ticker symbol ATEC. The company frequently participates in healthcare and medical technology conferences, including events hosted by organizations such as J.P. Morgan, North American Spine Society, and various investment banks. It also regularly hosts webcasts to discuss quarterly financial results and outlook.
ATEC uses current reports on Form 8-K to furnish press releases related to financial results and other material events, including quarterly earnings announcements and board-related matters. For example, Form 8-K filings reference press releases announcing financial results for periods ended June 30 and September 30, 2025, and a separate filing notes a press release regarding the passing of a board member.
Corporate focus and vision
Across its communications, Alphatec consistently describes itself as a spine-only company with a singular focus on spine surgery. Management commentary highlights the company’s intent to architect procedural solutions that integrate data, informatics, imaging, navigation, instrumentation, and biologics to improve predictability and outcomes in spine care. The company positions its culture and operations around this focus, referring to itself as "spine’s most relentless, deeply committed stewards" and emphasizing a long-term commitment to shaping standards in spine surgery.
Stock Performance
Alphatec Holdings (ATEC) closed at $8.28 on November 4, 2026. Over the past 12 months, the price has lost 57.4%.
ATEC Metrics & Rankings
Price returns through November 4, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Alphatec Holdings has 10 recent news articles, with the latest published 6 days ago. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, earnings date, conferences. View all ATEC news →
SEC Filings
Alphatec Holdings has filed 10 recent SEC filings, including 4 Form 4, 2 Form 10-Q, 2 Form 8-K, 1 Form 3. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ATEC SEC filings →
Insider Radar
Insider buying activity at Alphatec Holdings over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Alphatec Holdings generated $764.2M in revenue in FY2025, retaining a 69.6% gross margin, operating income reached -$82.1M (-10.8% operating margin), and net income was -$143.4M, reflecting a -18.8% net profit margin. Diluted earnings per share stood at -$0.96. The company generated $45.2M in operating cash flow. The current ratio was 2.06, measuring current assets divided by current liabilities.
Upcoming Events
Redemption eligibility begins
Convertible notes mature
Alphatec Holdings has 2 upcoming scheduled events. The next event, "Redemption eligibility begins", is scheduled for March 20, 2028 (in 502 days). All of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the ATEC stock price.
Short Interest History
Short interest in Alphatec Holdings (ATEC) currently stands at 13.3 million shares, down 5.6% from the previous reporting period, representing 10.9% of the float.
Days to Cover History
Days to cover for Alphatec Holdings (ATEC) currently stands at 5.9 days, down 15.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 2.2 to 10.0 days.
ATEC Company Profile & Sector Positioning
Alphatec Holdings (ATEC) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing ATEC often look at related companies in the same sector, including Artivion, Inc. (AORT), Enovis Corporation (ENOV), PROCEPT BioRobotics Corporation (PRCT), SI-BONE, Inc. (SIBN), and Tandem Diabetes Care, Inc. (TNDM). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ATEC's relative position within its industry.